Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/5927
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBalıbey, Hakan-
dc.contributor.authorBaşoğlu, Cengiz-
dc.contributor.authorLundgren, Stefan-
dc.contributor.authorBabaoğlu, Melih Ö.-
dc.contributor.authorYaşar, Ümit-
dc.contributor.authorHerken, Hasan-
dc.contributor.authorRane, Anders-
dc.contributor.authorBozkurt, Atilla-
dc.contributor.authorÇetin, Mesut-
dc.date.accessioned2019-08-16T12:03:14Z-
dc.date.available2019-08-16T12:03:14Z-
dc.date.issued2011-
dc.identifier.issn1017-7833-
dc.identifier.urihttps://hdl.handle.net/11499/5927-
dc.identifier.urihttps://doi.org/10.5455/bcp.20110622071701-
dc.description.abstractIntroduction: Genetic polymorphisms of cytochrome P450 (CYP) may predict the treatment response or occurrence of side effects of antipsychotic drugs. Aim: We studied the association of response to clozapine treatment in schizophrenic patients in relation to polymorphisms in the CYP1A2 gene. Methods: The degree of psychosis of the patients (n=55) was assessed using the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Positive Symptoms (SAPS), the Scale for the Assessment of Negative Symptoms (SANS) and routine biochemistry. The patients were monitored for 18 weeks and the scales were applied before starting the treatment and at the end of the follow up period. Clozapine was used at doses of 200 to 600 mg/day. A positive response was defined as a 20% decrease in pre-and posttreatment scores of one of the BPRS, SANS, or SAPS scores. In addition, 45 patients, who were already on clozapine treatment, were assessed retrospectively. Results: As assessed at the 18th week after start of therapy, lack of response to clozapine treatment was 2.4 fold higher in the patients carrying the CYP1A2*1F*1F genotype (p=0.02) compared to patients carrying at least one wild type allele (i.e. *1/*1 or *1/*1F). Smoking decreased the response rate by about 15% (p=0.014). Conclusion: The results of our study suggest that the CYP1A2*1F/*1F genotype may be a risk factor for lack of response to clozapine treatment in psychotic patients, especially in cigarette smokers.en_US
dc.language.isoenen_US
dc.relation.ispartofKlinik Psikofarmakoloji Bultenien_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectClozapineen_US
dc.subjectCYP1A2en_US
dc.subjectSchizophreniaen_US
dc.subjectSmokingen_US
dc.subjectclozapineen_US
dc.subjectcytochrome P450 1A2en_US
dc.subjectcytochrome P450 1A2 1Fen_US
dc.subjectunclassified drugen_US
dc.subjectadulten_US
dc.subjectarticleen_US
dc.subjectbiochemistryen_US
dc.subjectBrief Psychiatric Rating Scaleen_US
dc.subjectcigarette smokingen_US
dc.subjectdrug dose increaseen_US
dc.subjectdrug megadoseen_US
dc.subjectfemaleen_US
dc.subjectfollow upen_US
dc.subjectgene frequencyen_US
dc.subjectgenetic polymorphismen_US
dc.subjectgenotypeen_US
dc.subjecthumanen_US
dc.subjectmajor clinical studyen_US
dc.subjectmaleen_US
dc.subjectpsychologic assessmenten_US
dc.subjectpsychologic testen_US
dc.subjectpsychosisen_US
dc.subjectretrospective studyen_US
dc.subjectScale for the Assessment of Negative Symptomen_US
dc.subjectScale for the Assessment of Positive Symptomen_US
dc.subjectschizophreniaen_US
dc.subjectsingle nucleotide polymorphismen_US
dc.subjecttreatment durationen_US
dc.subjecttreatment responseen_US
dc.subjectwild typeen_US
dc.titleCYP1A2*1F polymorphism decreases clinical response to clozapine in patients with schizophreniaen_US
dc.typeArticleen_US
dc.identifier.volume21en_US
dc.identifier.issue2en_US
dc.identifier.startpage93-
dc.identifier.startpage93en_US
dc.identifier.endpage99en_US
dc.identifier.doi10.5455/bcp.20110622071701-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.scopus2-s2.0-79961099528en_US
dc.identifier.trdizinid141166en_US
dc.identifier.wosWOS:000294399000002en_US
dc.identifier.scopusqualityQ3-
dc.ownerPamukkale University-
item.openairetypeArticle-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextWith Fulltext-
item.grantfulltextopen-
item.cerifentitytypePublications-
crisitem.author.dept14.02. Internal Medicine-
Appears in Collections:Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Files in This Item:
File SizeFormat 
f78c31f0-aa7a-4003-acf1-d39625191b7d.pdf277.96 kBAdobe PDFView/Open
Show simple item record



CORE Recommender

SCOPUSTM   
Citations

23
checked on Nov 23, 2024

WEB OF SCIENCETM
Citations

20
checked on Nov 22, 2024

Page view(s)

52
checked on Aug 24, 2024

Download(s)

16
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.